BACKGROUND: Caris Molecular Intelligence ® (CMI) is a mul5pla7orm tumor profiling service helping pa5ents with refractory cancer who are past standard of care to find treatment op5ons. In the UK, the Na5onal Ins5tute for Health and Clinical Excellence (NICE) has implemented an end-of-life (EoL) premium since 2009.
RESULTS:
To date, NICE recommenda5ons have consistently used a £50,000 per QALY threshold for these EoL treatments. This equates to a health benefit of 7.3 days of addi5onal benefit per £1,000 expenditure. A CMI unit price of £5,000 was used in the ICER calcula5on. According to Caris registry data, CMI can extend overall survival by 138 days (or 0.378 years) for health economic evalua5on. CMIguided therapy is administered in 77% of profiled pa5ents, meaning that a decision impact factor of 0.77 could be included in ICER calcula5on. The ICER for CMI was calculated as CMI Cost / (QALYs gained x decision impact factor). Based on these assump5ons, the ICER for CMI is £17,180 or equivalent to 21.26 days benefit per £1,000 expenditure.
CONCLUSIONS:
Data from this model shows that CMI exceeds the threshold opportunity cost and represents value for health care systems that surpasses many recently approved drugs.
Methods

•
The average cost per QALY across all posi5ve recommenda5ons since EoL guidance was introduced in 2009 is approximately £49,000 per QALY.
• To date, these criteria have been met on 36 occasions and the commi`ee recommenda5ons have been consistent with the use of a £50,000 per QALY threshold for these EoL treatments.
• This equates to a health benefit of 7.3 days of addi5onal benefit per £1,000 expenditure by the health care system.
• To populate the model, this threshold cost and real-world incremental costeffec5veness ra5o (ICER) data from the health technology assessments performed by NICE in the past year (Nov 2015-December 2016) were used as comparators to show the value that CMI offers (all data was accessed on www.nice.org.uk).
• Based on the demonstra5on that CMI-guided treatments do not cost more than unguided treatment, and the assump5on that no profiling would be performed in the baseline case, the costs of CMI are considered to be addi5ve and an ICER for CMI was calculated based on the demonstrated survival benefit and clinical u5lity.
• A CMI unit price of £5,000 was used in the ICER calcula5on.
Results -Days Benefit per £1,000 spend on CMI
• In the Caris registry data, the median overall survival in the pa5ents without selec5on based on matched and unmatched treatment is 931 days.
•
The overall survival in pa5ents who received matched therapy only is 1069 days, indica5ng that CMI can extend overall survival by 138 days (or 0.378 years) for health economic evalua5on.
In addi5on, CMI can iden5fy the treatments associated with lack of benefit and thus could reduce ineffec5ve spend.
The median overall survival in the unmatched cohort is 686 days, 245 days (or 0.67 year) less than the median OS in the unselected popula5on. Note: The reduc5on of ineffec5ve spend associated with avoiding non-beneficial treatments is an added benefit for CMI that is not included in the calcula5on of the ICER.
Study Highlights -CMI Spend is favorably comparable to NICE threshold and approved drugs
• Per £1,000 spend, CMI brings 21.3 days benefit, exceeding the threshold of 7.3 days and comparable to that seen with nivolumab.
Results -Days Benefit per £1,000 spend in NICE-approved and rejected drugs
• The ICER per QALY gained for NICE-approved drugs varied from £18,324 to £45,159 (average = £37,766).
•
The days benefit per £1,000 spend for NICE-approved drugs in 2016 ranged from 8.09 to 19.93 days (average = 11.19 days).
The ICER per QALY gained for NICE-rejected drugs ranged from £150,514 to £194,919 (average = £171,782).
The days benefit per £1,000 spend for NICE-rejected drugs varied from 1.87 to 2.43 days (average = 2.15 days). 
Conclusions
• The addi5onal cost of performing CMI's mul5pla7orm tes5ng is likely to be offset by the addi5onal survival benefits observed, as long as it can be conclusively demonstrated that a tumour profiling service does not confer addi5onal treatment costs.
• Real-world observa5onal data can help to demonstrate the survival benefit needed to model the benefit in return for investment by a health care system.
• The benefit per £1,000 spend for CMI's mul5pla7orm profiling service exceeds the threshold for acceptance according to the NICE EoL criteria.
• Addi5onal modeling is needed to es5mate the financial impact of avoiding treatments which are not likely to work, and result in shorter survival 5mes.
Background
• The quality-adjusted life-year (QALY) is a generic measure of disease burden, including both the quality and the quan5ty of life lived. It is used in economic evalua5ons to assess the value for money of medical interven5ons. One QALY equates to one year in perfect health.
•
In the UK, the Na5onal Ins5tute for Health and Clinical Excellence (NICE) has implemented an end-of-life (EoL) premium since 2009. • NICE's methods guide a`ribute a greater weight to QALYs acquired in the later stages of terminal disease if three criteria could be fulfilled:
• prognosis less than 24 months, • small pa5ent popula5on, and • life-extension of at least three months compared to current NHS treatment.
The seing of a threshold for end of life treatment has been described in detail and used in assessment of new treatments and technologies to the healthcare system 1,2,3 .
In the assessment of the cost-effec5veness value of CMI in a health system below, a model described by McCabe and colleagues is adapted to show the value of CMI 4 .
The aim of this study is to assess the cost-effec5veness value of a mul5pla7orm tumor profiling service, Caris Molecular Intelligence ® (CMI) in helping pa5ents with refractory cancer who are past standard of care to find treatment op5ons in a health system. • Caris Life Sciences has established a post marke5ng Registry with the aim to complete a series of mul5centre prospec5ve observa5onal studies and developing an ongoing oncology molecular profiling-based clinical outcomes database as well as exploring and valida5ng exis5ng and novel biomarkers.
• An ini5al report from the Caris registry demonstrates that the overall survival of pa5ents with solid cancers treated with drugs associated with poten5al benefit according to a predic5ve biomarker panel was longer than in those who received drugs associated with poten5al lack of benefit.
The Caris registry is unique in that it gives us the data needed to calculate QALYs gained when pa5ents are treated in line with the CMI report.
931 1069 DAYS
Results -Calcula^on of Days Benefit per £1,000 spend on CMI
• CMI-guided therapy is administered in 77% of profiled pa5ents 5 , meaning that a clinical u5lity factor of 0.77 could be included in ICER calcula5on.
•
The ICER for CMI was calculated as Cost of CMI / (QALYs gained x clinical u5lity factor).
• Based on these assump5ons, the ICER for CMI is £17,180 or equivalent to 21.26 days benefit per £1,000 expenditure. 
